Patents Represented by Attorney, Agent or Law Firm Robert P. Blackburn
  • Patent number: 6677301
    Abstract: The present invention relates to a keratinocyte growth factor fragment, KGFdes1-23, or an analog thereof that is composed of a portion of an amino acid sequence of mature, full length keratinocyte growth factor, KGF163. The fragment exhibits at least a 2-fold increase in mitogenic activity as compared to a mature, recombinant keratinocyte growth factor, rKGF, but lacks a sequence comprising the first 23 amino acid residues. C-N-D-M-T-P-E-Q-M-A-T-N-V-N-C-S-S-P-E-R-H-T-R- (SEQ ID NO: 2) of the KGF163 N-terminus. The present invention also relates to a DNA molecule encoding KGFdes1-23, an expression vector and a transformed host containing the DNA molecule, and a method of producing KGFdes1-23 by culturing the transformed host. The present invention further relates to a conjugate of KGFdes1-23 and a toxin molecule, and the use thereof for treatment of hyperproliferative disease of the epidermis.
    Type: Grant
    Filed: May 16, 2000
    Date of Patent: January 13, 2004
    Assignee: Chiron Corporation
    Inventors: Denis J. Gospodarowicz, Frank R. Masiarz
  • Patent number: 6673911
    Abstract: A human oncogene and its expression products can be used as diagnostic, prognostic, and therapeutic tools for neoplastic disorders. Nucleotide sequences of the gene can also be used to identify a p34.3 region of a human chromosome 1.
    Type: Grant
    Filed: April 11, 2000
    Date of Patent: January 6, 2004
    Assignee: Chiron Corporation
    Inventor: Filippo M. Randazzo
  • Patent number: 6664054
    Abstract: The present invention provides the art with the DNA coding sequences of polynucleotides that are up- or down-regulated in cancer and dysplasia. These polynucleotides and encoded proteins or polypeptides can be used in the diagnosis or identification of cancer and dysplasia. Inhibitors of the up-regulated polynucleotides and proteins can decrease the abnormality of cancer and dysplasia. Enhancing the expression of down-regulated polynucleotides or introducing down-regulated proteins to cells can decrease the growth and/or abnormal characteristics of cancer and dysplasia.
    Type: Grant
    Filed: January 31, 2001
    Date of Patent: December 16, 2003
    Assignee: Chiron Corporation
    Inventor: Guilia C. Kennedy
  • Patent number: 6660471
    Abstract: This invention provides methods of generating cells that stably replicate sub-genomic virus replicons. This invention also provides methods of generating cells that have disabled PKR activity and that stably replicate HCV sub-genomic replicons. The invention also provides methods of using the cells of the invention to screen for compounds that modulate viral RNA replication, including HCV RNA replication.
    Type: Grant
    Filed: August 3, 2001
    Date of Patent: December 9, 2003
    Assignee: Chiron Corporation
    Inventors: Mark Selby, Hui-Hua Lu
  • Patent number: 6656720
    Abstract: Animal cells are described which can be infected by influenza viruses and which are adapted to growth in suspension in serum-free medium.
    Type: Grant
    Filed: July 12, 2002
    Date of Patent: December 2, 2003
    Assignee: Chiron Behring GmbH & Co.
    Inventors: Albrecht Gröner, Jürgen Vorlop
  • Patent number: 6656728
    Abstract: The invention relates to compositions and methods for inhibiting cell proliferation, especially angiogenesis. The invention specifically relates to fusions of the extracellular domain of a fibroblast growth factor receptor (FGFR) with a heterologous oligomerization domain, such as that contained in an immunoglobulin, to provide potent FGFR antagonists.
    Type: Grant
    Filed: February 7, 2000
    Date of Patent: December 2, 2003
    Assignee: Chiron Corporation
    Inventors: W. Michael Kavanaugh, Marcus Ballinger
  • Patent number: 6649374
    Abstract: A new recombinant form of the plasmid-encoded protein pgp3 from C. trachomatis, serotype D, to be used in immunogenic compositions and in the preparation of immunogenic compositions was purified by ion exchange column chromatography and shown to be suitable for quantitative immunoassy on clinical samples in an ELISA format.
    Type: Grant
    Filed: January 23, 1998
    Date of Patent: November 18, 2003
    Assignee: Chiron S.r.l.
    Inventor: Giulio Ratti
  • Patent number: 6642029
    Abstract: Methods and compositions are provided for efficient production of human insulin-like growth factor. Synthetic IGF I and IGF II genes are joined to leader and processing signals which provide for expression and secretion of the gene product in yeast. Enhanced yields of the product may then be recovered from the nutrient medium. Yeast strains S. cerevisiae AB103 (pYIGF-I-10/1) and AB103 (pYIGF-II-10/1) were deposited at the American Type Culture Collection on Apr. 23, 1983 and granted Accession Nos. 20673 and 20674, respectively.
    Type: Grant
    Filed: May 17, 1995
    Date of Patent: November 4, 2003
    Assignee: Chiron Corporation
    Inventors: Pablo D. T. Valenzuela, Guy Mullenbach
  • Patent number: 6642354
    Abstract: Novel bactericidal antibodies against Neisseria meningitidis serogroup B (“MenB”) are disclosed. The antibodies either do not cross-react or minimally cross-react with host tissue polysialic acid and hence pose minimal risk of autoimmune activity. The antibodies are used to identify molecular mimetics of unique epitopes found on MenB or E. coli K1. Examples of such peptide mimetics are described that elicit serum antibody capable of activating complement-mediated bacteriolysis of MenB. Vaccine compositions containing such mimetics can be used to prevent MenB or E. coli K1 disease without the risk of evoking autoantibody.
    Type: Grant
    Filed: July 23, 2001
    Date of Patent: November 4, 2003
    Assignees: Chiron Corporation, Children's Hospital Medical Center of Northern California
    Inventors: Dan M. Granoff, Gregory R. Moe
  • Patent number: 6638513
    Abstract: The present invention pertains generally to Neisseria meningitidis serogroup B glycoconjugates. More particularly, the invention pertains to glycoconjugates formed from a Neisseria meningitidis serogroup B capsular oligosaccharide derivative (MenB OS derivative) in which sialic acid residue N-acetyl groups are replaced with N-acyl groups. The invention also pertains to vaccine formulations containing the glycoconjugates, methods of making the vaccine formulations, and methods of using the vaccine formulations to treat or prevent Neisseria meningitidis serogroup B or E. coli K1 disease in a mammalian subject.
    Type: Grant
    Filed: August 7, 1997
    Date of Patent: October 28, 2003
    Assignee: Chiron S.r.l.
    Inventor: Robert Seid
  • Patent number: 6635748
    Abstract: Gene sequences as shown in SEQ ID NO:1-18 have been discovered and isolated, and found to be significantly associated with metastatic spread of breast and colon cancer cells to other organs. Methods are provided for determining the risk of metastasis of a breast or colon tumor, which involve determining whether a tissue sample from a tumor expresses a polypeptide encoded by a gene as shown in SEQ ID NOS:1-18, or a substantial portion thereof. One of the gene sequences encodes a novel aspartyl protease termed CSP56, which can be used to provide reagents and methods for determining which tumors are likely to metastasize and for suppressing metastases of these tumors. Clinicians can use this information to predict which tumors will metastasize to other organs and to provide relevant therapies to appropriate patients.
    Type: Grant
    Filed: December 17, 1998
    Date of Patent: October 21, 2003
    Assignee: Chiron Corporation
    Inventors: Hong Xin, Klaus Giese
  • Patent number: 6635258
    Abstract: Vaccines containing herpes simplex virus (HSV) VP22 polypeptides capable of eliciting a cellular immune response and methods for treating and preventing HSV infections using the vaccines are disclosed. The vaccines can include additional HSV polypeptides, such as HSV glycoproteins. Also disclosed are methods of DNA immunization.
    Type: Grant
    Filed: May 26, 1998
    Date of Patent: October 21, 2003
    Assignee: Chiron Corporation
    Inventors: Rae Lyn Burke, Michael A. Tigges
  • Patent number: 6632601
    Abstract: HCV immunoassays comprising an NS3/4a conformational epitope and a multiple epitope fusion antigen are provided, as well as immunoassay solid supports for use with the immunoassays.
    Type: Grant
    Filed: June 14, 2001
    Date of Patent: October 14, 2003
    Assignee: Chiron Corporation
    Inventors: David Y. Chien, Phillip Arcangel, Laura Tandeske, Carlos George-Nascimento, Doris Coit, Angelica Medina-Selby
  • Patent number: 6630298
    Abstract: An HCV core antigen and NS3/4a antibody combination assay that can detect both HCV antigens and antibodies present in a sample using a single solid matrix, is provided, as well as immunoassay solid supports for use in the assay.
    Type: Grant
    Filed: June 14, 2001
    Date of Patent: October 7, 2003
    Assignee: Chiron Corporation
    Inventors: David Y. Chien, Phillip Arcangel, Laura Tandeske, Carlos George-Nascimento, Doris Coit, Angelica Medina-Selby
  • Patent number: 6613956
    Abstract: Polynucleotide constructs encoding growth factor independent catalytically active membrane targeted PI 3-kinase mutants useful for therapeutic and research purposes are described. In addition, a method for using the polynucleotide constructs to screen for inhibitors of PI 3-kinase, a method for making 3′ phosphorylated inositol phospholipids, methods of reducing cell death after trauma, and methods of overcoming insulin resistance are described.
    Type: Grant
    Filed: April 2, 1997
    Date of Patent: September 2, 2003
    Assignee: Chiron Corporation
    Inventors: Anke Klippel, W. Michael Kavanaugh, Stephen D. Harrison, Lewis T. Williams
  • Patent number: 6608063
    Abstract: New bicyclic based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as in the treatment of diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.
    Type: Grant
    Filed: December 14, 2000
    Date of Patent: August 19, 2003
    Assignee: Chiron Corporation
    Inventors: John M. Nuss, Savithri Ramurthy
  • Patent number: 6605617
    Abstract: Organic compounds having the formulas I and II are provided where the variables have the values described herein. Pharmaceutical formulations include the organic compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and may be prepared by mixing the organic compounds or pharmaceutically acceptable salts of the organic compounds with a carrier and water. A method of treating a patient includes administering a pharmaceutical formulation according to the invention to a patient in need thereof.
    Type: Grant
    Filed: September 11, 2001
    Date of Patent: August 12, 2003
    Assignee: Chiron Corporation
    Inventors: Paul A. Renhowe, Sabina Pecchi, Timothy D. Machajewski, Cynthia M. Shafer, Clarke Taylor, William R. McCrea, Jr., Christopher McBride, Elisa Jazan
  • Patent number: 6605450
    Abstract: Methods and compositions for the expression of nucleotide sequences are provided. Compositions comprise the nucleic acid sequences of the transcriptional regulatory region of the PpSEC10 gene of Pichia pastoris. Methods are provided to chemically regulate the PpSEC10 transcriptional control region by modulating the iron concentration in the culturing medium. The methods find use in regulating expression of nucleotide sequences. Furthermore, the methods of the invention can be used to regulate polypeptide expression, more particularly in regulating heterologous polypeptide expression, particularly using a yeast host cell as the expression system.
    Type: Grant
    Filed: May 24, 2001
    Date of Patent: August 12, 2003
    Assignee: Chiron Corporation
    Inventors: Robert J. Bishop, Kenneth A. Crawford, Margaret M. Worden
  • Patent number: 6602705
    Abstract: The present invention relates to the efficient expression of HIV polypeptides in a variety of cell types, including, but not limited to, mammalian, insect, and plant cells. Synthetic expression cassettes encoding the HIV Gag-containing polypeptides are described, as are uses of the expression cassettes in applications including DNA immunization, generation of packaging cell lines, and production of Env-, tat- or Gag-containing proteins. The invention provides methods of producing Virus-Like Particles (VLPs), as well as, uses of the VLPs including, but not limited to, vehicles for the presentation of antigens and stimulation of immune response in subjects to whom the VLPs are administered.
    Type: Grant
    Filed: December 30, 1999
    Date of Patent: August 5, 2003
    Assignee: Chiron Corporation
    Inventors: Susan W. Barnett, Jan zur Megede, Catherine Greer, Mark Selby
  • Patent number: 6599706
    Abstract: Methods and materials are disclosed for the production of purified, active recombinant human neutrophil protease, PR-3, via activation of a pro-form herein referred to as proPR-3. Human PR-3 is useful for discovering inhibitors of excessive release of mature, active TNF&agr;. Also disclosed are methods for the identification of inhibitors of the conversion of the pro-form of TNF&agr; to its mature active form.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 29, 2003
    Assignee: Chiron Corporation
    Inventors: Robert F. Halenbeck, Michael Kriegler, Jan Tuttleman, Carl Perez, David A. Jewell, Kirston E. Koths